Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.84 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.84 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21853028 | 1.00 | ITGAV (0.84) | ITGAVITGB6ITGB3 | |
| SCHEMBL21852995 | 1.00 | ITGAV (0.84) | ITGAVITGB6ITGB3 | |
| SCHEMBL21853210 | 0.95 | ITGAV (0.92) | ITGAVITGB6ITGB3 | |
| SCHEMBL21853180 | 0.95 | ITGAV (0.92) | ITGAVITGB6ITGB3 | |
| SCHEMBL21853212 | 0.95 | ITGAV (0.92) | ITGAVITGB6ITGB3 | |
| SCHEMBL21853177 | 0.95 | ITGAV (0.92) | ITGAVITGB6ITGB3 | |
| SCHEMBL21853093 | 0.95 | ITGAV (0.92) | ITGAVITGB6ITGB3 | |
| SCHEMBL23547190 | 0.92 | ITGAV (0.75) | ITGAVITGB6ITGB3 | |
| SCHEMBL23547189 | 0.92 | ITGAV (0.75) | ITGAVITGB6ITGB3 | |
| SCHEMBL21852967 | 0.92 | ITGAV (0.81) | ITGAVITGB6ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112689507-B | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2024-07-30 | — | — | CN | claimed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20230060422-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. | 2023-03-02 | — | — | US | claimed |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-09-15 | — | — | US | claimed |
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | claimed |
| WO-2021127466-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | claimed |
| WO-2021127483-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | claimed |
| US-20200123151-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-23 | — | — | US | claimed |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-112689507-B | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2024-07-30 | — | — | CN | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230060422-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230055657-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230055657-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021127483-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127483-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127483-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127466-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| EP-3813818-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200123151-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ITGAV 8/4885ITGB6 2/4885ITGB3 11/4885 |
| US-20200123151-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | ITGAV 8/4885ITGB6 2/4885ITGB3 11/4885 |
| US-20230060422-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | SLC10A1, SLC5A1, ITGA1 | ITGAV 11/4885ITGB6 20/4885ITGB3 27/4885 |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | ITGAV 8/4885ITGB6 2/4885ITGB3 11/4885 |
| US-20230055657-A1 | COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS | NR1H4, ITGA1, ITGA4 | ITGAV 10/4885ITGB6 16/4885ITGB3 14/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ITGAV 8/4885ITGB6 2/4885ITGB3 11/4885 |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | ITGAV 8/4885ITGB6 2/4885ITGB3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.